![[Chart]](http://ichart.europe.yahoo.com/c/0b/d/drx.ir)
| | | Adresse: | Treasury Building, Lower Grand Canal Street
Dublin 2 Irelande | | Site Internet: | www.elan.com | | Indice: | STOXX600 | |
Marché(s)
: | Dublin | New York | Londres | Oslo | Vienne | |
Nombre d'actions
: | N/A | | Secteur: | Santé | | Industrie: | Pharmacie | | Sub-Industry: | Produits Pharmaceutiques |
|
| | Elan Corporation, neuroscience biotechnology.Elan is working together, through collaborations, core strengths and patient focus, to change lives.Elan is a neuroscience-based biotechnology company headquartered in Dublin, Ireland. Incorporated in December 1969 and it became public January 1984. Elan's principal research and development, manufacturing and marketing facilities are located in Ireland and the United States.Elan is organized into two business units: Biopharmaceuticals and Elan Drug Technologies.Biopharmaceuticals includes research, development, and commercial activities for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease; autoimmune diseases, including multiple sclerosis and Crohn's disease; and severe chronic pain.Elan Drug Technologies, the world's leading drug delivery business, develops and manufactures innovative pharmaceuticals using its extensive experience and proprietary drug technologies in partnership with pharmaceutical companies. For 40 years, EDT has enhanced the performance of dozens of drugs that are marketed and used by millions of patients worldwide.Elan and Johnson & Johnson announced on September 17, 2009, that JANSSEN Alzheimer Immunotherapy, a Johnson & Johnson affiliate, had acquired substantially all of Elan's assets related to the Alzheimer's Immunotherapy Program (AIP). JANSSEN Alzheimer Immunotherapy will continue the AIP activities in a collaboration with Wyeth to research, develop and commercialize selective products for the treatment and/or prevention of neurodegenerative conditions, including Alzheimer's disease. The program includes multiple compounds being evaluated for slowing the progression of Alzheimer's disease.The lead compound (bapineuzumab), a potential first-in-class treatment that is being evaluated for slowing the progression of Alzheimer's disease, is administered intravenously once every three months and is currently in Phase 3 clinical trials. A subcutaneous formulation, administered once a week, is currently in Phase 2 trials. In addition, a vaccine for Alzheimer's disease (ACC-001) is also under development. |
|
| ISIN: | IE0003072950 | | Code Reuters: | DRX.IR | |
Code Local
: | ELN | | Auditeur: | KPMG | | Nombre employés: | 1.687 ( 31/12/2008 )
1.734 ( 31/12/2007 ) |
|
| Pdt Conseil d'Administration: | Kyran McLaughlin | | Directeur Général: | Kelly Martin | | Directeur financier: | Shane Cooke | | Secrétaire général: | William Daniel | | Directeur Contrôle Interne: | Nigel Clerkin | | Ressources humaines: | Kathleen Martorano | | Dernière mise à jour le 30/09/2009 |
|
| Rapport annuel: | 19/02/2010 | | Réunion des actionnaires: | 27/05/2010 | | Profits 1er semestre: | 22/04/2010 |
|
| Public: | 54.6% | | Johnson & Johnson: | 18.4% | | Fidelity Mgt & Research: | 12.2% | | Wellington Management: | 5.2% | | Autres institutionnels < 3%: | 5.1% | | Barclays Global Investors: | 3.3% | | Dirigeants: | 1.2% |
|
| | |
Année
|
2007
|
2006
|
2005
|
2004
|
2003
| |
Chiffre d'Affaires*
| 516,4 | 497,3 | 426,7 | 464 | 762 | |
Résultat Net*
| -665,9 | -408,7 | 612,3 | -368,3 | -815,4 | | * en million(s) |
|
|
Année
|
2006
|
2005
|
2004
|
2003
| |
Bénéfice net par action*
| -0.62 | 1.48 | -0.94 | -2.29 |
|
| Produits biopharmaceutiques: | 61% | | Elan Drug Technologies: | 39% | | Dernière mise à jour le 31/12/2008 |
|
| VENTES PAR ZONE GEOGRAPHIQUE | |
| Marché principal | | Etats Unis | 65 |
|
| Zones Géographiques | | Usa: | 65% | | Europe: | 35% | | Dernière mise à jour le 31/12/2008 |
|
|
|
0,079 (1,54%)
Profil
Prix et données des Fonds fournis par:
